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Background: Platinum derivatives are used widely for the treatment of many cancers. However, the toxicity that is
observed makes imperative the need for new drugs, or new combinations. Anvirzel™ is an extract which has been
demonstrated with experimental data that displays anticancer activity. The aim of the present study is to determine
whether the combination of Cisplatin and Anvirzel™ has a synergistic effect against different types of cancer.
Materials and methods: To measure the efficacy of treatment with Cisplatin and Anvirzel™, methyl-tetrazolium
dye (MTT) chemosensitivity assays were used incorporating established human cancer cell lines. Measurements
were performed in triplicates, three times, using different incubation times and different concentrations of the two
formulations in combination or on their own. t-test was used for statistical analysis.
Results: In the majority of the cell lines tested, lower concentrations of Anvirzel™ induced a synergistic effect when
combined with low concentrations of Cisplatin after an incubation period of 48 to 72 h. The combination of
Anvirzel™/Cisplatin showed anti-proliferative effects against a wide range of tumours.
Conclusion: The results showed that the combination of Anvirzel™ and Cisplatin is more effective than
monotherapy, even when administered at low concentrations; thus, undesirable toxic effects can be avoided.
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Many studies demonstrate the anti-proliferative activity
of Oleandrin. These properties make it attractive for use
as a treatment for cancer [1-5]; however, a major prob-
lem is that Oleandrin is toxic to normal cells and tissues
[6,7]. Anvirzel™ is an extract of Nerium oleander com-
prised primarily of Oleandrin and Oleandrigenin [8].
Recent studies demonstrate that Anvirzel™ decreases
viability in prostate cancer cell lines as well as a wide
range of other human cancer cell lines [9-12]. Cisplatin
(CDDP) is a platinum-based chemotherapy drug used to
treat various types of cancer [13,14]. Because it is highly
toxic, and because of primary and secondary resistance
of cancer cells to Cisplatin [15], it is commonly used in
combination with other drugs [16,17]. A recent study* Correspondence: papasotiriou.ioannis@rgcc-genlab.com
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distribution, and reproduction in any mediumreported that the combination of Anvirzel™, Carboplatin
and Docetaxel is more effective than monotherapy [18].
Therefore, the aim of the current study was to deter-
mine whether the combination of Anvirzel™ and Cis-
platin was more effective than the use of either drug
alone using MTT chemosensitivity assays based on hu-
man cancer cell lines [19-23].Methods
The human carcinoma cell lines used were obtained
from the ECACC-HPA (European Collection of Cell
Cultures - Health Protective Agency, UK). PC3, LNCaP
and 22Rv1 are human prostate cancer cell lines, MDA-
MB 231, T47D, and MCF-7 are human breast cancer
lines, CALU-1, COLO699N and COR-L 105 are non-
small cell lung carcinoma lines (NSCLC), HCT-116,
HT55 and HCT-15 are colorectal cancer lines, and A375
and PANC-1 are melanoma and pancreatic cancer cellstral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 A. The illustration shows the effect of Anvirzel™ and Cisplatin, and their combination compared with the growth rate of cells
in cell line MCF-7 which represents breast cancer. B. The effect of the above drugs in monotherapy as well their combination compared with
the lethality of cells.
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used to determine the efficacy of combined treatment
compared with that each drug alone. The incubation times
used in the study were 24, 48 and 72 h at concentrations
ranging from 0.01 ng/ml to 10 ng/ml for Anvirzel™ and
from 0.1 μg/ml to 100 μg/ml for Cisplatin.
Cell lines
Cells were cultured in 75 cm2 flasks (Orange Scientific,
5520200) in the recommended media supplemented
with the appropriate amount of heat inactivated Fetal
Bovine Serum (FBS, Invitrogen, 10106–169, California)
and 2 mM L-Glutamine (Sigma, G5792, Germany). The
cells were maintained at 37°C in a 5% CO2 atmosphere.
Viability assays
Cells were detached by trypsinisation (Trypsin-0.25%
EDTA, Invitrogen, 25200–072) during the logarithmicFigure 2 A. The illustration shows the effect of Anvirzel™ and Cisplat
in cell line HCT-15 which represents colorectal cancer. B. The effect of
with the lethality of cells.phase of growth and plated in 96-well plates (Corning,
Costar 3595) at a density of 18,000 cells/well in a final
volume of 200 μl medium per well. When the cells
reached 70–80% confluence, the medium was removed
and Anvirzel™ (Salud Integral; diluted in water) and
Cisplatin (Sigma, P4394; diluted in N, N-dimethylforma-
mide; Fluka, 40255) were added to the cells at different
concentrations. Absorbance was measured after 24, 48
and 72 h of incubation.MTT assay
For the MTT assay, methyl-tetrazolium dye (Sigma,
M2128) was added to each well at a concentration of
5 mg/ml (diluted in PBS) and the plates incubated for
3 h at 37°C. The medium was then discarded and the
cells rinsed with PBS. Finally, the formazan crystals were
dissolved in dimethylsulphoxide (Sigma, D4540).in, and their combination compared with the growth rate of cells
the above drugs in monotherapy as well their combination compared
Figure 3 A. The illustration shows the effect of Anvirzel™ and Cisplatin, and their combination compared with the growth rate of cells
in cell line CALU-1 which represents NSCLC. B. The effect of the above drugs in monotherapy as well their combination compared with the
lethality of cells.
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ance was calculated using the Beer-Lambert law: A = εcl,
where “A” is the absorbance, “ε” is an extinction coeffi-
cient, “l” is the distance the light travels through the ma-
terial, and “c” is the concentration of the absorbing
species [24].
The optical density of the plate was measured using a
μQuant spectrophotometer (μQuant Biomolecular Spec-
trophotometer MQX200) and the data analysed with
Gen5 software (Gen5™ Microplate Data Collection &
Analysis software, BioTekW Instruments. Inc, April
2008). Absorbance was measured at 570 nm and a sec-
ond wavelength at 630 nm was measured to subtract
background “noise”.
Statistical analysis
All treatments for each cell line were performed in trip-
licate, three times. The statistical significance of allFigure 4 A. The illustration shows the effect of Anvirzel™ and Cisplat
in cell line PC3 which represents prostate carcinoma. B. The effect of t
with the lethality of cells.effects was evaluated using the “difference of the means”
test. A p value < 0.05 was considered significant.
Results
Different results were observed not only between each
type of cancer but also between each cell line within the
same carcinoma group. In all cell lines has been studied
LC50 (lethal concentration 50), which is the concentra-
tion that kill half of the sample population, and GI50
(growth inhibition 50), which is the concentration re-
quired to inhibit growth by 50%. In all cell lines tested,
administration of the combined formulation at lower
concentrations was more effective than monotherapy.
The formulation that elicited the most effective results
in most of the cell lines was a combination of 0.01 ng/
ml Anvirzel™ and 0.1 μg/ml Cisplatin, with incubation
period of 48 h or 72 h. The combination of 0.01 ng/ml
Anvirzel™ and 1 μg/ml Cisplatin was more effective inin, and their combination compared with the growth rate of cells
he above drugs in monotherapy as well their combination compared
Figure 5 A. The illustration shows the effect of Anvirzel™ and Cisplatin, and their combination compared with the growth rate of cells
in cell line PANC-1 which represents pancreatic cancer. B. The effect of the above drugs in monotherapy as well their combination
compared with the lethality of cells.
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MB231 cell lines. The Figures 1, 2, 3, 4, 5, 6 represent
data from cell lines that were tested both for Growth in-
hibition and for Lethal Concentrations.
Discussion
Anvirzel™ is an extract of Nerium oleander (family
Apocynaceae) that contains two toxic cardiac glycosides,
Oleandrin and Oleandrigenin [8], which have anti-
proliferative effects against various types of cancer.
According to literature data, Nerium oleander is often
used for its healing properties [25]. Oleandrin is used to
treat heart failure, and alters the levels of intracellular
K+ and Ca2+ [26]. Other studies show that Oleandrin
suppresses the activation of many transcription factors
and enhances the radiosensitivity of tumours [27,28].
Oleandrin induces cell death through the activation ofFigure 6 A. The illustration shows the effect of Anvirzel™ and Cisplat
in cell line A375 which represents melanoma cancer. B. The effect of th
with the lethality of cells.caspases in a variety of human tumour cells, as well as
by activating calcineurin and NF-AT via the Fas ligand
[3]. Recent studies of Anvirzel™ in prostate cell lines
show that it interacts with the membrane Na+/K+-
ATPase and thus inhibits the export of FGF-2 [11,28].
Cisplatin is a platinum-based chemotherapy drug widely
used to treat various types of cancer [13,14]. In high con-
centrations, Cisplatin is highly cytotoxic. In addition,
tumour cells often develop resistance to treatment [15].
Many studies demonstrate that administration of Cis-
platin in combination with other treatments is more
effective and produces fewer toxic effects. The present
study aimed the demonstrate the synergistic effect of
Anvirzel™ and Cisplatin in a wide range of cell lines,
which represent the most common types of cancer. It
was used the methyl-tetrazolium dye assay, which is used
to measure the activity of enzymes in the mitochondria.in, and their combination compared with the growth rate of cells
e above drugs in monotherapy as well their combination compared
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reduced by the mitochondrial enzymes to yield formazan,
which is purple/blue [19,20].
It has been confirmed that Anvirzel™ has better activ-
ity at lower concentrations in many cancer cell lines,
after 48 or 72 h of incubation. In contrast, low Cisplatin
concentrations (<1 μg/ml), do not indicate activity in the
same cells. The effect of platinum is evident at concen-
trations greater than 10 μg/ml. However, these concen-
trations have high cytotoxicity effects. The combination
of the two formulations at very low concentrations is
able to inhibit cell growth by more than 50% in an ex-
posure time of 72 hours. The same concentration may
also reduce the number of live cells at rates up to 85% in
the same time of exposure. Lowered effect observed in
cell lines that are hormone-dependent, cases such as
breast and prostate cancer.Conclusions
The MTT viability assays were used to test the hypothesis
that combined treatment with Cisplatin and Anvirzel™
would be more effective than either drug alone. The results
of all three assays were both concentration and cell line-
dependent. It is noteworthy that increased efficacy was ob-
served at lower concentrations of both substances, 0.01 ng/
ml for Anvirzel™ and 0.1 μg/ml for Cisplatin, than of either
drug alone. The results were neither reliable nor reprodu-
cible at higher concentrations of Anvirzel™ and Cisplatin.
The results were also time-dependent: treatment was effect-
ive after 48 h and 72 h of incubation, but not after 24 h.
The present study contributes to demonstrate an effect-
ive interaction between Anvirzel™ and another widely
used drug with cytostatic effects. Based on these data, it is
crucial to perform further studies to identify and
characterize the interaction between Anvirzel™ and other
drugs currently used to treat cancer.
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